Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy

Journal of Market Access & Health Policy
Panos KefalasMatthew Durdy

Abstract

Background: Market access stakeholders consider the adoption of Managed Entry Agreements (MEAs), however a clearly described methodology to quantify their implementation burden is not available in the public domain. Objective: To quantify the cost of implementing a performance-based MEA at the hospital level. Methods: The analysis involved a hypothetical one-off therapy targeting Acute Lymphoblastic Leukaemia. Data collection from five NHS Hospital Trusts in England captured costs by task, job band, personnel time and capital investment. We compared the administrative burden of the standard of care (SoC) to that of adopting the therapy with or without an MEA over 10 years. Findings: The 10-year cost for the activities required to support hospital payments for the target patient population in England varied as follows: for the SoC was £447,353, compared to £1,117,024 for the novel therapy with MEA, and £245,317 without MEA. Conclusions: The higher cost associated with the SoC compared to the novel therapy without an MEA, arises from the higher frequency of infusions requiring payments and the associated mandatory data capturing requirements for oncology therapies. The novel therapy with MEA presents the greatest burden due to in...Continue Reading

References

Dec 10, 2014·Journal of the Royal Society of Medicine·Katelijne van de VoorenLivio Garattini

❮ Previous
Next ❯

Citations

May 3, 2019·AJNR. American Journal of Neuroradiology·H A ValandR K Tu
Sep 24, 2020·International Journal of Technology Assessment in Health Care·Weiwei Xu, Jing Wu
Jun 5, 2020·British Journal of Clinical Pharmacology·Andrew R ChampionDyfrig A Hughes
Aug 3, 2021·Journal of Managed Care & Specialty Pharmacy·Diana BrixnerAlexander Niyazov

❮ Previous
Next ❯

Software Mentioned

NICE Technology Appraisal ( TA )
BlueTeq
SACT
Excel

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.